Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I
- PMID: 11754109
- DOI: 10.1002/humu.9001
Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I
Abstract
Thirteen Israeli patients with type I tyrosinemia were studied. To the best of our knowledge, this group represents all of the patients that were diagnosed in Israel during the years 1987-1997. Their age of onset was variable but all the patients suffered from liver disease at presentation. Six died at 3 to 36 months of age, whereas the remaining 7, in whom NTBC was started at 5 to 30 months, are alive and well at 4 to 11 years. Three mutations were identified: a mis-splicing IVS8-1G>C mutation in a large Moslem kindred, Pro261Leu mutation in all Jewish patients, and the IVS12+5G>A mutation, commonly found in French Canadian patients.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients.Hum Mutat. 2002 Sep;20(3):180-8. doi: 10.1002/humu.10084. Hum Mutat. 2002. PMID: 12203990
-
Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.J Pediatr Endocrinol Metab. 2016 Mar;29(3):327-32. doi: 10.1515/jpem-2015-0289. J Pediatr Endocrinol Metab. 2016. PMID: 26565546
-
Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.Mol Genet Metab. 1998 Jun;64(2):119-25. doi: 10.1006/mgme.1998.2695. Mol Genet Metab. 1998. PMID: 9705236
-
The genetic tyrosinemias.Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):121-6. doi: 10.1002/ajmg.c.30092. Am J Med Genet C Semin Med Genet. 2006. PMID: 16602095 Review.
-
Molecular Aspects of the FAH Mutations Involved in HT1 Disease.Adv Exp Med Biol. 2017;959:25-48. doi: 10.1007/978-3-319-55780-9_3. Adv Exp Med Biol. 2017. PMID: 28755182 Review.
Cited by
-
Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1.Metabol Open. 2021 Jan 28;9:100083. doi: 10.1016/j.metop.2021.100083. eCollection 2021 Mar. Metabol Open. 2021. PMID: 33598652 Free PMC article.
-
The homogentisate pathway: a central catabolic pathway involved in the degradation of L-phenylalanine, L-tyrosine, and 3-hydroxyphenylacetate in Pseudomonas putida.J Bacteriol. 2004 Aug;186(15):5062-77. doi: 10.1128/JB.186.15.5062-5077.2004. J Bacteriol. 2004. PMID: 15262943 Free PMC article.
-
Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.Medicine (Baltimore). 2019 Sep;98(39):e17303. doi: 10.1097/MD.0000000000017303. Medicine (Baltimore). 2019. PMID: 31574857 Free PMC article.
-
Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.JIMD Rep. 2015;19:43-58. doi: 10.1007/8904_2014_363. Epub 2015 Feb 15. JIMD Rep. 2015. PMID: 25681080 Free PMC article.
-
Identification of Novel Mutations in FAH Gene and Prenatal Diagnosis of Tyrosinemia in Indian Family.Case Rep Genet. 2012;2012:428075. doi: 10.1155/2012/428075. Epub 2012 Oct 30. Case Rep Genet. 2012. PMID: 23193487 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous